» Articles » PMID: 9204210

Model SV40-transformed Fibroblast Lines for Metabolic Studies of Human Prosaposin and Acid Ceramidase Deficiencies

Overview
Journal Clin Chim Acta
Specialty Biochemistry
Date 1997 Jun 27
PMID 9204210
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Skin fibroblasts from patients with Farber disease (acid ceramidase deficiency) and from two siblings of the only known family affected with prosaposin deficiency were transformed by transfection with a plasmid carrying the SV40 large T antigen. The prosaposin-deficient transformed cell lines conserved their original metabolic defects, and in particular they were free of detectable immunoreactivity when using anti-saposin B and anti-saposin C antisera. Ultrastructurally, the cells contained heterogeneous lysosomal storage products. As found for their parental cell lines, the SV40-transformed fibroblasts exhibited deficient in vitro activities of lysosomal ceramidase and beta-galactosylceramidase, but a normal activity of acid sphingomyelinase. As observed for SV40-transformed fibroblasts from Farber disease, degradation of radioactive glucosylceramide or low density lipoprotein-associated radiolabelled sphingomyelin by the prosaposin-deficient cells in situ showed a clear impairment in the turnover of lysosomal ceramide. Ceramide storage in prosaposin-deficient cells was also demonstrated by ceramide mass determination. In contrast to acid ceramidase deficient cells, both the accumulation of ceramide and the reduced in vitro activity of acid ceramidase in cells from prosaposin deficiency could be corrected by addition of purified saposin D. The data confirm that prosaposin is required for lysosomal ceramide degradation, but not for sphingomyelin turnover. The SV40-transformed fibroblasts will be useful for pathophysiological studies on human prosaposin deficiency.

Citing Articles

Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice.

He X, Dworski S, Zhu C, DeAngelis V, Solyom A, Medin J BBA Clin. 2017; 7:85-96.

PMID: 28275553 PMC: 5338723. DOI: 10.1016/j.bbacli.2017.02.001.


Characterization and application of a disease-cell model for a neurodegenerative lysosomal disease.

Ribbens J, Moser A, Hubbard W, Bongarzone E, Maegawa G Mol Genet Metab. 2013; 111(2):172-83.

PMID: 24094551 PMC: 3946682. DOI: 10.1016/j.ymgme.2013.09.011.


Accumulation of ordered ceramide-cholesterol domains in farber disease fibroblasts.

Ferreira N, Goldschmidt-Arzi M, Sabanay H, Storch J, Levade T, Ribeiro M JIMD Rep. 2013; 12:71-7.

PMID: 23846911 PMC: 3897794. DOI: 10.1007/8904_2013_246.


A high-throughput screening assay using Krabbe disease patient cells.

Ribbens J, Whiteley G, Furuya H, Southall N, Hu X, Marugan J Anal Biochem. 2012; 434(1):15-25.

PMID: 23138179 PMC: 3975245. DOI: 10.1016/j.ab.2012.10.034.


A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease.

Bedia C, Camacho L, Abad J, Fabrias G, Levade T J Lipid Res. 2010; 51(12):3542-7.

PMID: 20871013 PMC: 2975727. DOI: 10.1194/jlr.D010033.